Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cork

Showing results (141-150 of 224) with videos related to

Pageof 23
Sort By:
Clinical and Experimental Dermatology|February 15, 2022
Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitisSimon G Danby, Paul V Andrew, Rosie N Taylor, et al.
The Journal of Biological Chemistry|April 14, 2009
Defining the structural basis of human plasminogen binding by streptococcal surface enolaseAmanda J Cork, Slobodan Jergic, Sven Hammerschmidt, et al.
Paediatric Drugs|January 24, 2024
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Dermatology and Therapy|July 22, 2023
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 YearsElaine C Siegfried, Eric L Simpson, Michael J Cork, et al.
The Journal of Investigative Dermatology|June 5, 2009
Epidermal barrier dysfunction in atopic dermatitisMichael J Cork, Simon G Danby, Yiannis Vasilopoulos, et al.
American Journal of Clinical Dermatology|May 14, 2024
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension StudyAmy S Paller, Elaine C Siegfried, Eric L Simpson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2025
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by AgeMichael J Cork, Mette Deleuran, Bob Geng, et al.
Mbio|April 25, 2022
Streptococcus pyogenes Hijacks Host Glutathione for Growth and Innate Immune EvasionStephan Brouwer, Magnus G Jespersen, Cheryl-Lynn Y Ong, et al.
Toxins|October 24, 2017
Production, Characterisation and Testing of an Ovine Antitoxin against Ricin; Efficacy, Potency and Mechanisms of ActionSarah J C Whitfield, Gareth D Griffiths, Dominic C Jenner, et al.
Mbio|December 17, 2024
Characterization of a novel <i>covS</i> SNP identified in Australian group A <i>Streptococcus</i> isolates derived from the M1<sub>UK</sub> lineageJohanna Richter, Amanda J Cork, Yvette Ong, et al.
Pageof 23

Showing results (141-150 of 224) with videos related to

Sort By:
Pageof 23
Clinical and Experimental Dermatology|February 15, 2022
Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitisSimon G Danby, Paul V Andrew, Rosie N Taylor, et al.
The Journal of Biological Chemistry|April 14, 2009
Defining the structural basis of human plasminogen binding by streptococcal surface enolaseAmanda J Cork, Slobodan Jergic, Sven Hammerschmidt, et al.
Paediatric Drugs|January 24, 2024
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Dermatology and Therapy|July 22, 2023
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 YearsElaine C Siegfried, Eric L Simpson, Michael J Cork, et al.
The Journal of Investigative Dermatology|June 5, 2009
Epidermal barrier dysfunction in atopic dermatitisMichael J Cork, Simon G Danby, Yiannis Vasilopoulos, et al.
American Journal of Clinical Dermatology|May 14, 2024
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension StudyAmy S Paller, Elaine C Siegfried, Eric L Simpson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2025
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by AgeMichael J Cork, Mette Deleuran, Bob Geng, et al.
Mbio|April 25, 2022
Streptococcus pyogenes Hijacks Host Glutathione for Growth and Innate Immune EvasionStephan Brouwer, Magnus G Jespersen, Cheryl-Lynn Y Ong, et al.
Toxins|October 24, 2017
Production, Characterisation and Testing of an Ovine Antitoxin against Ricin; Efficacy, Potency and Mechanisms of ActionSarah J C Whitfield, Gareth D Griffiths, Dominic C Jenner, et al.
Mbio|December 17, 2024
Characterization of a novel <i>covS</i> SNP identified in Australian group A <i>Streptococcus</i> isolates derived from the M1<sub>UK</sub> lineageJohanna Richter, Amanda J Cork, Yvette Ong, et al.
Pageof 23